Michael Davitz quoted in IP Law & Business

IP Law & Business quotes Michael Davitz in their October 2007 issue:  Get Used to It: With Glivec, Novartis had found a breakthrough cancer treatment, and it hoped India's new patent laws would protect its innovative drug.  Here's how a poorly waged patent battle metastasized into an international controversy.  "New U.S. Patent and Trademark Office rules that aim to limit the endless continuations filed on pharma patents will also make it more difficult for drug companies to protect their incremental innovations," says Michael Davitz, former in-house counsel for Israeli generics maker Taro Pharmaceuticals, now with Axinn, Veltrop & Harkrider.  "India is doing it explicitly with section 3(d)," Davitz says.  "The U.S. is doing it more implicitly."